CAMP4 Therapeutics closes second tranche of $100M private placement, raising $50.1M

Camp4 Therapeutics Corp

Second closing gross proceeds $50.1M from 10.76M shares at $1.53 and 21.93M pre-funded warrants at $1.5299.
Total private placement $100M; proceeds to fund CMP-002 Phase 1/2 trial for SYNGAP1-related disorder.
Investors include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage Capital, Trails Edge, CURE SYNGAP1.
Pre-funded warrants exercisable at $0.0001, subject to 19.99% beneficial ownership limitation.
Securities issued in private placement not registered under Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.